Evidence map›Paper›PMID 37484374›Full record

ArticleHeliyon2023

A novel approach to achieve semi-sustained drug delivery to the eye through asymmetric loading of soft contact lenses.

Malake Sarmout, Yutang Xiao, Xiao Hu, Aiym Rakhmetova, Leo H Koole

Abstract read
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Malake SarmoutInnovative Engineering Laboratory for Ocular Drug Delivery, Eye Hospital of Wenzhou Medical University, School of Ophthalmology and Optometry, Wenzhou, China.
Yutang XiaoInnovative Engineering Laboratory for Ocular Drug Delivery, Eye Hospital of Wenzhou Medical University, School of Ophthalmology and Optometry, Wenzhou, China.
Xiao HuInnovative Engineering Laboratory for Ocular Drug Delivery, Eye Hospital of Wenzhou Medical University, School of Ophthalmology and Optometry, Wenzhou, China.
Aiym RakhmetovaInnovative Engineering Laboratory for Ocular Drug Delivery, Eye Hospital of Wenzhou Medical University, School of Ophthalmology and Optometry, Wenzhou, China.
Leo H KooleInnovative Engineering Laboratory for Ocular Drug Delivery, Eye Hospital of Wenzhou Medical University, School of Ophthalmology and Optometry, Wenzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Soft contact lenses are increasingly being explored as a vehicle for controlled delivery of ophthalmic drugs. However, traditional methods of drug-loading by soaking have limitations such as burst delivery and the release of drugs at the front side of the lens, leading to poor drug efficacy and systemic side effects. This study introduces a new methodology, termed asymmetric drug loading, whereby the ophthalmic drug 'Rebamipide' is attached to and released from the post-lens (=cornea-contacting) surface exclusively. The methodology involves using polymeric microparticles that carry a lipophilic crystalline ophthalmic drug at their surface. These drug-loaded microparticles first transfer the drug to the concave surface of the contact lens, and when worn, the drug is transferred again, now from the lens to the cornea. This is achieved through the diffusion of the drug from one hydrophobic microenvironment (the silicone moieties of the contact lens polymer network) to another hydrophobic microenvironment (the corneal epithelium) over a short pathway. The second drug transfer was observed and studied in experiments using an

Indexed as

Contact lensCorneaDrug-eluting contact lensMicroparticlesOcular drug deliveryRebamipide

Identifiers

PMID37484374
PMCPMC10360931

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.